Novel small molecules illustrate potential cost effective approach for
TSX Exchange Symbol: RVX
CALGARY and ATLANTA, May 19 /CNW/ - Resverlogix Corp. ("Resverlogix" or
the "Company") (TSX:RVX) is pleased to announce today that it has made
significant advancement in the Company's research and development (R&D)
program for inflammatory diseases. Two new patent applications have been filed
for novel compounds and their use in regulating inflammatory markers.
Inflammatory markers are proteins generated by the body during periods of
inflammation. These patents were filed based on the successful results
demonstrated in numerous preclinical studies across several disease areas. The
particular results achieved in the collagen induced arthritis (CIA) model in
rats demonstrated that Resverlogix's proprietary molecules markedly reduced
inflammation while improving mobility of arthritic animals.
"Resverlogix's R&D program has made significant strides this past year,"
said Donald J. McCaffrey, President & CEO of Resverlogix. "The Company has
identified several molecules that have the potential for disease modifying
effects in inflammatory disorders such as rheumatoid arthritis. Resverlogix's
R&D team is continuing to examine the various disease indications in
inflammation which would have the greatest potential impact for both patients
and payer groups," continued McCaffrey.
A significant unmet medical need exists for safe, effective and
economical therapies for specific inflammation markets. For example, a small
molecular drug for rheumatoid arthritis is estimated to range in price from US
$180 - US $6000 per person per annum. A biologic, or large molecule drug, can
cost in the order of US $13,000 - US $30,000 per patient per annum. In 2007,
the global market for rheumatoid arthritis alone was estimated to be in excess
of US $11 billion a year and is expected to grow to US $27 billion by the year
2015. These important markets require novel therapies to reduce pain and
symptoms in a cost efficient manner. Resverlogix's novel small molecules have
the illustrated early potential to fill this important gap.
Kenneth Lebioda, Senior Vice President of Business & Corporate
Development of Resverlogix stated, "The inflammation market is enormous with
many significant unmet needs. Current leading therapeutics such as biologics
are effective, but also very expensive. Resverlogix's platform technology has
created novel small molecules which illustrate potent anti-inflammatory
effects in arthritis models as compared with leading biologic agents." Lebioda
highlighted, "The early efficacy data from these compounds is exciting for the
reason that small molecules would offer significant cost savings to health
systems over current biologic agents."
Inflammation is a normal response of the body to protect tissues from
infection, injury or disease. Though it promotes healing, if uncontrolled, the
inflammatory response may become harmful. Acute or chronic inflammation is
known to play a key role in diverse disease states, such as atherosclerosis
and rheumatoid arthritis. Worldwide it is estimated that more than 80 million
people suffer from inflammatory diseases.
Resverlogix will be presenting at the BIO Business Forum held at the
Convention Center in Atlanta, Georgia on Wednesday, May 20, 2009 at 9:20 am
EDT in Room 313.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) PR program is the Company's primary
focus which is to develop novel small molecules that enhance ApoA-I. These
vital therapies address the grievous burden of atherosclerosis and other
important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's
disease, Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information
please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email: